\thispagestyle {empty}
\contentsline {chapter}{\numberline {1}Review of computational drug repositioning approaches}{15}{chapter.1}
\contentsline {section}{\numberline {1.1}Relevance of drug repositioning}{16}{section.1.1}
\contentsline {subsection}{\numberline {1.1.1}Opportunities for finding new indications}{17}{subsection.1.1.1}
\contentsline {subsection}{\numberline {1.1.2}Drug repositioning faces legal and scientific challenges}{20}{subsection.1.1.2}
\contentsline {section}{\numberline {1.2}Drug repositioning and indication discovery: success stories}{21}{section.1.2}
\contentsline {subsection}{\numberline {1.2.1}Sildenafil: repositioning from clinical side-effects}{22}{subsection.1.2.1}
\contentsline {subsection}{\numberline {1.2.2}Thalidomide: repositioning a hazardous drug}{23}{subsection.1.2.2}
\contentsline {subsection}{\numberline {1.2.3}Raloxifene: expanding the application line}{24}{subsection.1.2.3}
\contentsline {section}{\numberline {1.3}Computational approaches towards drug repositioning}{25}{section.1.3}
\contentsline {subsection}{\numberline {1.3.1}Chemical structure-based approaches}{26}{subsection.1.3.1}
\contentsline {subsection}{\numberline {1.3.2}Gene expression and functional genomics-based approaches}{28}{subsection.1.3.2}
\contentsline {subsection}{\numberline {1.3.3}Protein structure and molecular docking-based approaches}{31}{subsection.1.3.3}
\contentsline {subsection}{\numberline {1.3.4}Phenotype and side-effect-based approaches}{34}{subsection.1.3.4}
\contentsline {subsection}{\numberline {1.3.5}Genetic variation-based approaches}{36}{subsection.1.3.5}
\contentsline {subsection}{\numberline {1.3.6}Disease network-based approaches}{38}{subsection.1.3.6}
\contentsline {subsection}{\numberline {1.3.7}Machine learning and concepts combination approaches}{40}{subsection.1.3.7}
\contentsline {subsection}{\numberline {1.3.8}Summary}{42}{subsection.1.3.8}
\contentsline {section}{\numberline {1.4}Thesis: biological process and molecular function for drug repositioning}{46}{section.1.4}
\contentsline {subsection}{\numberline {1.4.1}Rationale}{46}{subsection.1.4.1}
\contentsline {subsection}{\numberline {1.4.2}Towards the specification, implementation and analysis}{48}{subsection.1.4.2}
\contentsline {subsubsection}{\numberline {1.4.2.1}Chapter 2 - Description logics and biomedical knowledge (Specification)}{49}{subsubsection.1.4.2.1}
\contentsline {subsubsection}{\numberline {1.4.2.2}Chapter 3 - The Functional Therapeutic Chemical Classification System (Implementation)}{49}{subsubsection.1.4.2.2}
\contentsline {subsubsection}{\numberline {1.4.2.3}Chapter 4 - Systematic drug repositioning analysis}{50}{subsubsection.1.4.2.3}
\contentsline {subsubsection}{\numberline {1.4.2.4}Chapter 5 - Outlook and future work}{50}{subsubsection.1.4.2.4}
\contentsline {chapter}{\numberline {2}Description logics and biomedical knowledge (Specification)}{51}{chapter.2}
\contentsline {section}{\numberline {2.1}Introduction}{52}{section.2.1}
\contentsline {section}{\numberline {2.2}Biomedical knowledge}{53}{section.2.2}
\contentsline {subsection}{\numberline {2.2.1}Contemporary formalism in biomedical sciences}{53}{subsection.2.2.1}
\contentsline {subsubsection}{\numberline {2.2.1.1}Formalism varies among natural sciences}{53}{subsubsection.2.2.1.1}
\contentsline {subsubsection}{\numberline {2.2.1.2}Organisms as complex machines}{56}{subsubsection.2.2.1.2}
\contentsline {subsection}{\numberline {2.2.2}Requirements for biomedical knowledge formalisation}{59}{subsection.2.2.2}
\contentsline {subsubsection}{\numberline {2.2.2.1}Mathematical framework}{59}{subsubsection.2.2.2.1}
\contentsline {subsubsection}{\numberline {2.2.2.2}Definitions}{60}{subsubsection.2.2.2.2}
\contentsline {subsubsection}{\numberline {2.2.2.3}Hierarchies and abstraction}{60}{subsubsection.2.2.2.3}
\contentsline {subsubsection}{\numberline {2.2.2.4}Distributed and scalable}{61}{subsubsection.2.2.2.4}
\contentsline {subsubsection}{\numberline {2.2.2.5}Molecular dynamism}{62}{subsubsection.2.2.2.5}
\contentsline {section}{\numberline {2.3}Description logics for biomedical knowledge representation}{63}{section.2.3}
\contentsline {subsection}{\numberline {2.3.1}Problems addressed by description logics}{63}{subsection.2.3.1}
\contentsline {subsection}{\numberline {2.3.2}Expressivity and complexity}{65}{subsection.2.3.2}
\contentsline {subsection}{\numberline {2.3.3}DLs' components and relation to life sciences}{67}{subsection.2.3.3}
\contentsline {subsubsection}{\numberline {2.3.3.1}Description logics entities}{68}{subsubsection.2.3.3.1}
\contentsline {paragraph}{\textbf {Named Individuals}\\}{68}{subsubsection.2.3.3.1}
\contentsline {paragraph}{\textbf {Concepts}\\}{68}{subsubsection.2.3.3.1}
\contentsline {paragraph}{\textbf {Roles}\\}{69}{figure.caption.25}
\contentsline {subsubsection}{\numberline {2.3.3.2}Axioms}{70}{subsubsection.2.3.3.2}
\contentsline {paragraph}{\textbf {Assertional axioms (ABox)}\\}{70}{subsubsection.2.3.3.2}
\contentsline {subparagraph}{Concept assertion\\}{70}{subsubsection.2.3.3.2}
\contentsline {subparagraph}{Role assertion\\}{70}{subsubsection.2.3.3.2}
\contentsline {paragraph}{\textbf {Terminological axioms (TBox)}\\}{71}{subsubsection.2.3.3.2}
\contentsline {subparagraph}{Concept inclusion ($ \sqsubseteq $)\\}{71}{subsubsection.2.3.3.2}
\contentsline {subparagraph}{Concept equivalence ($ \equiv $)\\}{72}{figure.caption.26}
\contentsline {paragraph}{\textbf {Relational axioms (RBox)}\\}{72}{figure.caption.26}
\contentsline {subparagraph}{Role inclusion ($ \sqsubseteq $)\\}{72}{figure.caption.26}
\contentsline {subsubsection}{\numberline {2.3.3.3}Constructors}{72}{subsubsection.2.3.3.3}
\contentsline {paragraph}{\textbf {Intersection ($ \sqcap $)}\\}{72}{figure.caption.27}
\contentsline {paragraph}{\textbf {Existential Restriction ($ \exists $)}\\}{73}{figure.caption.27}
\contentsline {paragraph}{\textbf {Role composition ($ \circ $)}\\}{75}{figure.caption.28}
\contentsline {subsection}{\numberline {2.3.4}Reasoning services}{76}{subsection.2.3.4}
\contentsline {subsection}{\numberline {2.3.5}The Web Ontology Language 2 (OWL2)}{78}{subsection.2.3.5}
\contentsline {section}{\numberline {2.4}Implementation with life-science information}{79}{section.2.4}
\contentsline {subsection}{\numberline {2.4.1}Integration with biomedical ontologies}{79}{subsection.2.4.1}
\contentsline {subsubsection}{\numberline {2.4.1.1}Open Biomedical Ontologies (OBO)}{79}{subsubsection.2.4.1.1}
\contentsline {subsubsection}{\numberline {2.4.1.2}Approximations and assumptions}{81}{subsubsection.2.4.1.2}
\contentsline {subsection}{\numberline {2.4.2}Integration with databases}{84}{subsection.2.4.2}
\contentsline {subsection}{\numberline {2.4.3}Brain library - implementing programmatic solutions}{85}{subsection.2.4.3}
\contentsline {section}{\numberline {2.5}Summary}{87}{section.2.5}
\contentsline {chapter}{\numberline {3}The Functional Therapeutic Chemical Classification System (Implementation)}{91}{chapter.3}
\contentsline {section}{\numberline {3.1}Introduction}{92}{section.3.1}
\contentsline {section}{\numberline {3.2}Method and definitions}{95}{section.3.2}
\contentsline {subsection}{\numberline {3.2.1}Source code}{95}{subsection.3.2.1}
\contentsline {subsection}{\numberline {3.2.2}Categories creation}{96}{subsection.3.2.2}
\contentsline {subsubsection}{\numberline {3.2.2.1}Mode of Action categories}{96}{subsubsection.3.2.2.1}
\contentsline {subsubsection}{\numberline {3.2.2.2}Mechanism of Action categories}{97}{subsubsection.3.2.2.2}
\contentsline {subsection}{\numberline {3.2.3}Equivalent definitions}{97}{subsection.3.2.3}
\contentsline {subsubsection}{\numberline {3.2.3.1}Regulatory pattern}{97}{subsubsection.3.2.3.1}
\contentsline {subsubsection}{\numberline {3.2.3.2}Functional pattern}{100}{subsubsection.3.2.3.2}
\contentsline {subsection}{\numberline {3.2.4}Data integration}{101}{subsection.3.2.4}
\contentsline {subsubsection}{\numberline {3.2.4.1}Drugbank}{101}{subsubsection.3.2.4.1}
\contentsline {subsubsection}{\numberline {3.2.4.2}Gene Ontology Annotations (GOA)}{104}{subsubsection.3.2.4.2}
\contentsline {subsection}{\numberline {3.2.5}Knowledge base classification}{104}{subsection.3.2.5}
\contentsline {subsection}{\numberline {3.2.6}Evaluation methodology}{105}{subsection.3.2.6}
\contentsline {subsubsection}{\numberline {3.2.6.1}Evaluation Points}{106}{subsubsection.3.2.6.1}
\contentsline {subsubsection}{\numberline {3.2.6.2}True Positives}{107}{subsubsection.3.2.6.2}
\contentsline {subsubsection}{\numberline {3.2.6.3}False Negatives}{107}{subsubsection.3.2.6.3}
\contentsline {subsubsection}{\numberline {3.2.6.4}False Positives}{107}{subsubsection.3.2.6.4}
\contentsline {subsubsection}{\numberline {3.2.6.5}Precision}{107}{subsubsection.3.2.6.5}
\contentsline {subsubsection}{\numberline {3.2.6.6}Recall}{107}{subsubsection.3.2.6.6}
\contentsline {subsection}{\numberline {3.2.7}Semantic similarity}{108}{subsection.3.2.7}
\contentsline {subsection}{\numberline {3.2.8}Mode of action similarity against indication}{108}{subsection.3.2.8}
\contentsline {subsection}{\numberline {3.2.9}Knowledge base specification}{109}{subsection.3.2.9}
\contentsline {subsubsection}{\numberline {3.2.9.1}Core FTC classes}{109}{subsubsection.3.2.9.1}
\contentsline {paragraph}{molecular function}{109}{subsubsection.3.2.9.1}
\contentsline {paragraph}{biological process}{109}{subsubsection.3.2.9.1}
\contentsline {paragraph}{Protein}{109}{subsubsection.3.2.9.1}
\contentsline {paragraph}{Drug}{110}{subsubsection.3.2.9.1}
\contentsline {paragraph}{therapeutic agent}{110}{subsubsection.3.2.9.1}
\contentsline {paragraph}{DrugBank compound}{110}{subsubsection.3.2.9.1}
\contentsline {subsubsection}{\numberline {3.2.9.2}Core FTC properties}{110}{subsubsection.3.2.9.2}
\contentsline {paragraph}{part-of}{110}{subsubsection.3.2.9.2}
\contentsline {paragraph}{has-part}{111}{subsubsection.3.2.9.2}
\contentsline {paragraph}{regulates}{111}{subsubsection.3.2.9.2}
\contentsline {paragraph}{negatively-regulates}{111}{subsubsection.3.2.9.2}
\contentsline {paragraph}{positively-regulates}{111}{subsubsection.3.2.9.2}
\contentsline {paragraph}{involved-in}{112}{subsubsection.3.2.9.2}
\contentsline {paragraph}{has-function}{112}{subsubsection.3.2.9.2}
\contentsline {paragraph}{perturbs}{112}{subsubsection.3.2.9.2}
\contentsline {paragraph}{negatively-perturbs}{113}{subsubsection.3.2.9.2}
\contentsline {paragraph}{postively-perturbs}{113}{subsubsection.3.2.9.2}
\contentsline {section}{\numberline {3.3}The classification}{113}{section.3.3}
\contentsline {section}{\numberline {3.4}Evaluation}{116}{section.3.4}
\contentsline {section}{\numberline {3.5}Exploration}{117}{section.3.5}
\contentsline {subsection}{\numberline {3.5.1}Polypharmacology spectrum}{117}{subsection.3.5.1}
\contentsline {subsection}{\numberline {3.5.2}Drugs with similar functions have similar indications}{119}{subsection.3.5.2}
\contentsline {section}{\numberline {3.6}Discussion}{124}{section.3.6}
\contentsline {subsection}{\numberline {3.6.1}Biological assumptions}{125}{subsection.3.6.1}
\contentsline {subsection}{\numberline {3.6.2}Interpreting the evaluation}{126}{subsection.3.6.2}
\contentsline {section}{\numberline {3.7}Summary}{127}{section.3.7}
\contentsline {chapter}{\numberline {4}Systematic drug repositioning analysis}{129}{chapter.4}
\contentsline {section}{\numberline {4.1}Introduction}{130}{section.4.1}
\contentsline {section}{\numberline {4.2}Structure, function and indication of drugs}{131}{section.4.2}
\contentsline {subsection}{\numberline {4.2.1}Structural descriptor selection}{131}{subsection.4.2.1}
\contentsline {subsection}{\numberline {4.2.2}Dissimilar structures have dissimilar functions}{134}{subsection.4.2.2}
\contentsline {subsection}{\numberline {4.2.3}The more specific an indication is, the more similar the function and structure are}{138}{subsection.4.2.3}
\contentsline {subsection}{\numberline {4.2.4}Isolation of drug repositioning hypotheses}{146}{subsection.4.2.4}
\contentsline {section}{\numberline {4.3}Open drug repositioning hypotheses}{148}{section.4.3}
\contentsline {subsection}{\numberline {4.3.1}Relationship between therapeutic areas}{149}{subsection.4.3.1}
\contentsline {subsection}{\numberline {4.3.2}Drug repositioning for hypertension and the cardiovascular system}{153}{subsection.4.3.2}
\contentsline {subsubsection}{\numberline {4.3.2.1}Antihypertensives}{155}{subsubsection.4.3.2.1}
\contentsline {subsubsection}{\numberline {4.3.2.2}Calcium channel blockers}{159}{subsubsection.4.3.2.2}
\contentsline {subsubsection}{\numberline {4.3.2.3}Adrenergic receptor antagonists}{161}{subsubsection.4.3.2.3}
\contentsline {subsubsection}{\numberline {4.3.2.4}Alpha-2 agonists}{163}{subsubsection.4.3.2.4}
\contentsline {subsubsection}{\numberline {4.3.2.5}Diuretics}{164}{subsubsection.4.3.2.5}
\contentsline {subsubsection}{\numberline {4.3.2.6}Renin-angiotensin system}{166}{subsubsection.4.3.2.6}
\contentsline {paragraph}{\textbf {Angiotensin-converting enzyme (ACE) inhibitors}\\}{167}{figure.caption.77}
\contentsline {paragraph}{\textbf {Angiotensin II receptor antagonists}\\}{168}{figure.caption.77}
\contentsline {paragraph}{\textbf {Renin inhibitors}\\}{168}{figure.caption.77}
\contentsline {paragraph}{\textbf {Aldosterone receptor antagonists}\\}{169}{figure.caption.77}
\contentsline {subsubsection}{\numberline {4.3.2.7}Peripheral vasodilators}{169}{subsubsection.4.3.2.7}
\contentsline {subsection}{\numberline {4.3.3}Repositioning for Alzheimer's disease}{172}{subsection.4.3.3}
\contentsline {section}{\numberline {4.4}Summary}{175}{section.4.4}
\contentsline {section}{\numberline {4.5}Methods}{177}{section.4.5}
\contentsline {subsection}{\numberline {4.5.1}Structural fingerprints calculation}{177}{subsection.4.5.1}
\contentsline {subsection}{\numberline {4.5.2}Structural similarity between drugs}{177}{subsection.4.5.2}
\contentsline {subsection}{\numberline {4.5.3}Agreement between fingerprinting methodologies}{178}{subsection.4.5.3}
\contentsline {subsection}{\numberline {4.5.4}Kernel density plots}{178}{subsection.4.5.4}
\contentsline {subsection}{\numberline {4.5.5}Web application related to drug repositioning hypotheses}{179}{subsection.4.5.5}
\contentsline {subsection}{\numberline {4.5.6}Filtering of drug repositioning hypotheses}{180}{subsection.4.5.6}
\contentsline {subsection}{\numberline {4.5.7}Filtering of relationships between therapeutic areas}{180}{subsection.4.5.7}
\contentsline {chapter}{\numberline {5}Outlook and future work}{181}{chapter.5}
\contentsline {section}{\numberline {5.1}Work performed in the context of the drug discovery process}{182}{section.5.1}
\contentsline {section}{\numberline {5.2}Comparison against functional genomics}{183}{section.5.2}
\contentsline {section}{\numberline {5.3}Biomedical knowledge: towards a simpler representation}{184}{section.5.3}
\contentsline {section}{\numberline {5.4}Off-label uses and clinical drug repositioning}{185}{section.5.4}
\contentsline {chapter}{Bibliography}{186}{section.5.4}
\contentsline {chapter}{\numberline {A}Glossary}{187}{appendix.A}
\contentsline {chapter}{\numberline {B}Abbreviations}{189}{appendix.B}
\contentsline {chapter}{\numberline {C}Peer-reviewed publications}{191}{appendix.C}
\contentsline {chapter}{\numberline {D}Side-projects}{193}{appendix.D}
